Technology Archives - Page 5 of 11 - Boston Life Sciences Times

Agenus Reports Durable Responses in Refractory Ovarian Cancer With Botensilimab and Balstilimab

December 23, 2025

Quanterix Nature Study Redefines Prevalence of Alzheimer’s Disease Neuropathology in General Population

December 22, 2025

Alnylam to Invest $250 Million to Expand U.S. Manufacturing With Enzymatic Ligation Platform

December 17, 2025

THIS WEEK'S STORIES

ENHERTU Granted FDA Breakthrough Therapy Designation as Post-Neoadjuvant Treatment for HER2-Positive Early Breast Cancer

December 22, 2025

Quanterix Nature Study Redefines Prevalence of Alzheimer’s Disease Neuropathology in General Population

December 22, 2025

Viridian Therapeutics Secures FDA Acceptance and Priority Review for Veligrotug in Thyroid Eye Disease

December 22, 2025

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Technology

Quantori, Expert Systems Partner to Advance Predictive AI in Drug Discovery

eClinicalWorks, Sunoh.ai Help AssociatesMD Boost Productivity and Expand Access to Care

CellTivity Scientific Receives CE Registration for Van Gogh Microscopy System, Expanding Diagnostic Use Across Europe

Mobile Heartbeat Announces New Voice Enhancements and Resiliency Features for Clinical Communication Platform

Revvity Introduces Signals Xynthetica AI Platform for Molecular and Materials Discovery

Most Read

FDA Approves Edwards Lifesciences’ SAPIEN M3 as First Transseptal Transcatheter Mitral Valve Replacement

RevBio Receives FDA Clearance to Launch Dental Clinical Trial for Regenerative Bone Glue

Enveda Advances Third Drug Candidate Into Clinic With FDA Clearance for ENV-6946

Startup Shutdowns Shift to Later Stages as First AI Reckoning Emerges, Report Finds

EDITOR PICKS

Agenus Reports Durable Responses in Refractory Ovarian Cancer With Botensilimab and Balstilimab

Quanterix Nature Study Redefines Prevalence of Alzheimer’s Disease Neuropathology in General Population

Alnylam to Invest $250 Million to Expand U.S. Manufacturing With Enzymatic Ligation Platform

THIS WEEK'S STORIES

ENHERTU Granted FDA Breakthrough Therapy Designation as Post-Neoadjuvant Treatment for HER2-Positive Early Breast Cancer

Quanterix Nature Study Redefines Prevalence of Alzheimer’s Disease Neuropathology in General Population

Viridian Therapeutics Secures FDA Acceptance and Priority Review for Veligrotug in Thyroid Eye Disease

POPULAR CATEGORY

ABOUT US

FOLLOW US